Immunome (IMNM) vs Trevi Therapeutics (TRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Trevi Therapeutics (TRVI) has outperformed Immunome (IMNM) over the past year, gaining 21.5% versus a loss of 15.3%. Over five years, TRVI leads with a +1235.0% price change compared with -7.5% for IMNM. Trevi Therapeutics is the larger company by market cap ($1.90 billion vs $1.85 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | TRVI |
|---|---|---|
| Share price | $15.69 | $13.35 |
| Market cap | $1.85B | $1.90B |
| 1-day change | -5.54% | -2.70% |
| YTD return | -26.96% | +6.63% |
| 1-year return | -15.33% | +21.47% |
| 5-year return | -7.54% | +1235.00% |
| EPS (TTM) | $-2.63 | $-0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.94M | — |
| Revenue growth (YoY) | -23.23% | — |
| Net income (latest FY) | $-212.39M | $-42.76M |
| Operating margin | -3228.83% | — |
| Net margin | -3059.99% | — |
| 52-week high | $30.06 | $20.22 |
| 52-week low | $15.55 | $9.82 |
| Distance from 52-week high | -47.80% | -33.98% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +123.90% | +111.09% |
| Average volume | 1.36M | 2.00M |
| Shares outstanding | 118.07M | 142.56M |
| Employees | 267 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRVI has outperformed IMNM by 36.8 percentage points over the past year.
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 267 employees
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
IMNM vs TRVI FAQ
Which is bigger, Immunome or Trevi Therapeutics?
Trevi Therapeutics (TRVI) is larger, with a market capitalization of $1.90B compared with $1.85B for Immunome (IMNM).
Which stock has performed better over the past year, IMNM or TRVI?
TRVI returned +21.47% over the past 12 months, compared with -15.33% for IMNM (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and Trevi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.